Introduction
Fabry's disease (angiokeratoma corporis diffusum universale or trihexosylceramidosis) is an uncommon Xlinked inherited catabolic disorder characterized [22, 23] by the accumulation of large amounts of trihexosylceramide, galactosyl-a-(l -> 4)-galactosyl-/?-(l -» 4)-glucosyl-/3-(l -> l)-2-2V-acylsphingosine [7] , in visceral tissue and the additional accumulation of digalactosylceramide, galactosyl-«-(l -> 4)-galactosylceramide [12] , in kidney. Although the central nervous system is essentially unaffected, periodic crises of pain occur and this may be explained by the accumulation of GL-3 in the dorsal root ganglia [21, 23] . Death eventually results from renal failure in the 3rd decade of life or later [23] . As with many sphingolipidoses, the clinical severity is variable, possibly because of different intragenic mutations at the Fabry locus, and there have been a number of reports [23] of heterozygotes who manifest an attenuated form of the disease.
The biochemical defect in Fabry's disease was shown to be a galactosidase deficiency by Brady et al. [2] and 684 a-Galactosidase from ficin in Fabry's disease 685 more specifically, an ct-galactosidase deficiency, by Kint [10] . Fibroblasts cultured from the skin of Fabry patients exhibited both the chemical [16] and the enzymic [20] abnormality. Further, Romeo and Migeon [20] have demonstrated that fibroblasts from obligate heterozygotes could be cloned into normal and affected cell strains, the heterozygote cultures with 50% of normal enzymic activity. Mapes et al. [13] have demonstrated the presence of GL-3-a-galactosidase activity in normal human plasma and suggested that plasma infusion might be a useful therapeutic measure for treating this visceral storage disease. The initial success of enzyme replacement by plasma infusion [14] , which may have stimulated the de novo synthesis of enzyme, has prompted the use of organ transplantation (such as renal) as a means of more permanent enzyme replacement [18, 23] . However, recent improvements in enzyme purification have indicated that replacement with pure a-galactosidase might eventually be practical. Thus Mapes and Sweeley [15] have demonstrated that human plasma Cohn fraction IV-I can be separated into three major a-galactosidase fractions after affinity chromatography on a column of melibiose coupled to succinylated Sepharose. Two of the fractions cleaved human kidney trihexosylceramide, but not synthetic a-galactosides, and had different pH optima and. different sialic acid content (accounting for the different electrophoretic mobility of the a-galactosidases [1] ). The third fraction showed activity only toward p-nitrophenyl-a-D-galactoside, which indicates that caution should be used in interpreting results with synthetic substrates.
Fibroblasts have been used as a model for enzyme replacement in the severe neurologic disease, metachromatic leukodystrophy (MLD) [19, 25] , and arylsulfatase A activity was then measurable for several weeks in culture. However, MLD fibroblasts do not normally accumulate sulfatide, necessitating the addition of sulfatide to the medium before the enzyme replacement. In contrast, Fabry fibroblasts accumulate trihexosylceramide naturally so that enzyme replacement in these cells may have greater physiologic significance. Since Fabry's disease does not involve the central nervous system to an appreciable extent, thus avoiding the blood-brain barrier problem encountered with MLD or the mucopolysaccharidoses [17] , successful replacement with this stable purified plant enzyme [11] should indicate a useful means of in vivo therapy when the human enzyme becomes available.
Materials and Methods
Enzyme Purification a-Galactosidase was purified from commercially available ficin [27] by a combination of acetone precipitation, Bio-Gel P-60 column chromatography, ammonium sulfate (80% saturation) precipitation, DEAESephadex A-50 chromatography, and final ammonium sulfate precipitation (0.8 saturation) as described previously [7] . The precipitate from an original 10 g ficin was dissolved in 1 ml 0.05 M sodium phosphate buffer, pH 7.0, and tested for activity against both GL-3 and p-nitrophenyl-a-D-galactoside [7, 11] . Studies with other commercially available synthetic substrates showed it to be free of contaminating lysosomal hydrolases. One unit of enzyme hydrolyzes 1 /unol p-nitrophenyl-a-Dgalactopyranoside or 0.01 //.mol trihexosylceramide/ min at 25° under in vitro conditions.
Chemical Analysis
Fibroblasts for analytic studies (approximately 1 X 10 8 cells are needed for each analysis) were grown for 4 weeks to maximum density (2.5 X 10 7 cells/plate) under the same conditions as described. Glycosphingolipids were isolated and characterized as described previously [4] .
Enzyme Replacement
Fribroblasts were cultured from skin biopsies obtained from patients who exhibited, both clinically and biochemically, the classic symptoms of sphingolipid storage diseases; all cultures were assayed for lysosomal hydrolase levels. The Fabry cells used for enzyme replacement studies were plated initially at a density of 1 x 10 8 cells/100-mm Falcon petri dish in modified Eagle's medium [26] supplemented with ascorbic acid (100 mg/liter), 10% fetal calf serum and 10% calf serum [4] . After 7 days of growth, the cells were labeled with U-14 C-glucose (10 /xCi/plate, specific activity 270 ^Ci/^mol) for 48 hr. At this time the medium was removed and replaced by fresh medium containing a-galactosidase (0.1-1.0 units/plate). Control plates were re-fed with standard medium. After 6 hr, a further addition of 0.1-1.0 units of enzyme was made (enzyme concentration was 1 unit/ 15 /A in 0.05 M sodium phosphate buffer, pH 7.0). Cells were harvested after 24 hr of growth in the presence of enzyme and individual glycosphingolipids isolated as described previously [3, 24] . Radioactivity was determined by liquid scintillation counting after extraction of glyco- lipids [3] from silica gel after thin layer chromatography. Enzymic analyses for a-galactosidase activity were carried out as previously described [5, 10, 20] on cells and media at a number of time intervals after the addition of purified a-galactosidase to the medium (1 unit/plate of 4 X 10 6 fibroblasts in monolayer culture).
Results and Discussion
Although human skin fibroblasts cultured from patients with storage diseases exhibit the enzymic defect found in the donor patient, it is not always possible to demonstrate actual storage. Studies in this laboratory [5, 16] have shown that chemical abnormalities can be detected in fibroblasts from patients with Fabry's disease, Gaudier's disease, lactosylceramidosis, and Sandhoff-Jatzkewitz disease (G M2 -gangliosidosis type II) (Fig. 1) , but other lipidoses such as metachromatic and globoid cell leukodystrophies or G M1 -gangliosidosis. Of the enzymes involved in these four diseases, only a-galactosidase and /J-iV-acetylhexosaminidase have been purified to any great extent [7, 9, 11] . Since Fabry's disease does not include brain pathology, the prospects for effective enzyme reeplacement therapy were considered to be optimal and the fibroblast system was deemed a suitable model to determine whether exogenous enzyme could be incorporated into pre-existing lysosomes of a cell.
Uptake of arGalactosidase by Fibroblasts
Initial studies on the stability of ficin a-galactosidase in tissue culture medium (Fig. 2) indicated a loss of 70% of activity during the first 6 hr, after which the rate of loss was much more gradual. Neither fresh nor conditioned medium from normal cells was found to contain any a-galactosidase activity. Analyses of Fabry fibroblasts after exposure to enzyme revealed that under the conditions described, a-galactosidase activity rose from near 0 to the hydrolysis of 0.2 pxaol galactose/mg protein/hr, which is the mean activity of the native a-galactosidase in fibroblasts (Table I ). In contrast to studies with arylsulfatase A [19] , the ficin a-galactosidase was fairly rapidly inactivated within the (Fig. 3 ) indicated a slightly higher stability for the intracellular a-galactosidase but over 50% of the enzymic activity was lost between 6 and 24 hr after addition of a-galactosidase. Over this period, 88% of the a-galactosidase was lost from the medium but despite the apparently different rate of loss, negligible activity was detected in either cells or medium after 72 hr.
Detection of Trihexosylceramide Catabolism
Because the uptake of a-galactosidase by Fabry cells could be readily demonstrated, it was necessary to devise a sensitive assay system to detect the catabolism of GL-3 and other glycosphingolipids. We have shown previously [5] that all glycosphingolipids in human cultured skin fibroblasts are rapidly labeled when U- [ 14 C]-glucose is present in the medium and that Fabry fibroblast GL-3 retains this label specifically. The difference in GL-3 concentration between treated and untreated cells was investigated after exposure to different levels of a-galactosidase. Table II shows that adding 1 unit of enzyme to fibroblasts derived from patients I and // resulted in a negligible (6%) amount of catabolism. However, with higher concentrations of enzyme (Table II) , 6 units hydrolyzed 79% of the GL-3 in patient II (Fig. 4) , and 8 units hydrolyzed 96% of the GL-3 in patient I. Since the glycosphingolipids were counted directly and not fractionated into their hexose, fatty acid, and sphingosine moieties [4] it is possible that GL-la values could reflect some contamination from labeled neutral lipid. Other minor anomalies found in GL-2a and GL-4 levels may similarly reflect some artifact but the dramatic reduction in the level of GL-3, which can be seen visually (Fig. 4) , is obviously the major effect.
Subcellular Site of Enzyme Incorporation and Substrate Catabolism
The assumption that GL-3 in Fabry's disease is stored within lysosomes has to some extent been confirmed by electron microscopy [28] , although at present we have no direct proof. It, therefore, appears that a-galactosidase is incorporated into existing lysosomes in an active form inasmuch as stored GL-3 is actually catabolized. The data presented in Table I and Figures 2 and 3 suggest that the specific activity of the enzyme is the same in both cells and medium. However, it must be pointed out that, inasmuch as the protein content of the medium is much higher than that of the cells, the efficiency of uptake of enzyme is much less than it would appear.
Enzyme Replacement Therapy "in Vivo"
Future development of enzyme replacement therapy may depend on artificial stabilization of the ficin a-galactosidase, possibly by chemical modification or encapsulation, the purification of a human a-galactosidase [15] which should overcome the immunologic problems associated with a plant enzyme and could have greater in vivo stability, and the demonstration that parenchymal cells other than fibroblasts are capable of taking up the enzyme. However, plasma replacement studies in Fabry's disease [14] have indicated that human a-galactosidase is lost from the plasma at a rate approximately equal to that of our plant enzyme in tissue culture medium, and purified human p-N-acetylhexosaminidase A had a similarly brief half-life in the plasma of a G M2 -gangliosidosis type II patient [6] . This might suggest that the brief half-life of our plant enzyme might be typical of human a-galactosidase also but it is possible that the loss of enzymic activity from the plasma represented uptake by cells such as hepatocytes. The advantage of the ficin enzyme for these fibroblast studies is its great in vitro stability, enabling it to be shipped in soluble form without refrigeration or elaborate packing. The studies of Neufeld et al. [17] indicate that human lysosomal enzymes, partially purified from urine, retain the ability to "correct" enzymic deficiencies in fibroblasts from patients with mucopolysaccharide storage disorders. However, previous studies on mammalian a-galactosidases [2, 13] have indicated a relatively low activity toward GL-3 compared with the ficin enzyme [29] , whereas preparations from Aspergillus niger or Moriterella vinacea [7] showed high reactivity toward the synthetic a-galactoside but none toward GL-3. The feasibility of administering to a patient an enzyme derived from a plant would appear to be extremely unlikely but a precedent does exist from in vivo studies on a child with type II glycogen storage disease, with the use of glycogen-degrading enzymes prepared from A. niger [8] . Recent advances in the purification of human a-galactosidase [15] suggest that a-Galactosidase from ficin in Fabry's disease 689 the human enzyme could be used for in vivo enzyme replacement provided that one can demonstrate its efficiency in a tissue culture system such as the one described. The use of plant enzymes would appear to be essentially preclinical in providing a rational biochemical basis for replacement therapy. It is tempting to speculate that a combination of heterozygote detection and prenatal diagnosis, together with enzyme replacement therapy, will provide an effective management of these inborn errors of metabolism in children.
Summary
Fibroblasts cultured from skin biopsies obtained from patients with Fabry's disease were almost totally deficient in a-galactosidase activity and accumulated a four-sixfold excess of trihexosylceramide compared with normal fibroblasts grown under the same conditions. Fabry fibroblasts, in which the stored trihexosylceramide had been labeled with 14 C-glucose, were treated with a purified a-galactosidase from ficin, resulting in the catabolism of up to 95% of the stored lipid. This finding suggests that purified enzymes can enter pre-existing lysosomes and degrade the accumulating lipid, and provides support for the concept of enzyme replacement therapy for visceral lipid storage diseases.
